<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://www.gourt.com/Health/Pharmacy/Drugs-and-Medications/B/Bortezomib.html">
<title>Bortezomib RSS : Gourt</title>
<link>http://www.gourt.com/Health/Pharmacy/Drugs-and-Medications/B/Bortezomib.html</link>
<description></description>
<dc:language>en-us</dc:language>
<dc:rights>Copyright 2007, Gourt.com</dc:rights>
<dc:date>2012-02-09T08:18+37:00
</dc:date>
<dc:publisher>rtruog@gourt.com</dc:publisher>
<dc:creator>rtruog@gourt.com</dc:creator>
<dc:subject>Bortezomib RSS : Gourt</dc:subject>
<syn:updatePeriod>hourly</syn:updatePeriod>
<syn:updateFrequency>1</syn:updateFrequency>
<syn:updateBase>1901-01-01T00:00+00:00</syn:updateBase>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://twitter.com/inhibidordela/statuses/167571846848450560" />
  <rdf:li rdf:resource="http://twitter.com/inibitore/statuses/167568463924166656" />
  <rdf:li rdf:resource="http://twitter.com/inhibiteurs/statuses/167564219867340800" />
  <rdf:li rdf:resource="http://twitter.com/inhibiteurs/statuses/167564218680356864" />
  <rdf:li rdf:resource="http://twitter.com/inhibiteurs/statuses/167564217518534656" />
  <rdf:li rdf:resource="http://twitter.com/sogaizai/statuses/167562549238317056" />
  <rdf:li rdf:resource="http://twitter.com/cellpharmanews/statuses/167562028700012545" />
  <rdf:li rdf:resource="http://twitter.com/cellsignalings/statuses/167562026967777280" />
  <rdf:li rdf:resource="http://twitter.com/cellsignalings/statuses/167541304652345344" />
  <rdf:li rdf:resource="http://twitter.com/cellsignalings/statuses/167541297358446592" />
  <rdf:li rdf:resource="http://twitter.com/cellcycles/statuses/167535549396168704" />
  <rdf:li rdf:resource="http://twitter.com/sogaizai/statuses/167532003854524417" />
  <rdf:li rdf:resource="http://twitter.com/sogaizai/statuses/167532002441039872" />
  <rdf:li rdf:resource="http://twitter.com/eogjeje/statuses/167531065110560768" />
  <rdf:li rdf:resource="http://twitter.com/eogjeje/statuses/167531064095539200" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://twitter.com/inhibidordela/statuses/167571846848450560">
<title>Rechazamientos m&#xC3;&#xBA;ltiples de Hyperacute en la ausencia de activaci&#xC3;&#xB3;n perceptible del complemento con Bortezomib.:  http://t.co/4Q7dItPI</title>
<link>http://twitter.com/inhibidordela/statuses/167571846848450560</link>
<description><![CDATA[Rechazamientos múltiples de Hyperacute en la ausencia de activación perceptible del complemento con Bortezomib.:  http://t.co/4Q7dItPI]]></description>
</item>

<item rdf:about="http://twitter.com/inibitore/statuses/167568463924166656">
<title>Rifiuti multipli di Hyperacute in assenza di attivazione rilevabile del complemento con Bortezomib.:  http://t.co/JfdJtb2X</title>
<link>http://twitter.com/inibitore/statuses/167568463924166656</link>
<description><![CDATA[Rifiuti multipli di Hyperacute in assenza di attivazione rilevabile del complemento con Bortezomib.:  http://t.co/JfdJtb2X]]></description>
</item>

<item rdf:about="http://twitter.com/inhibiteurs/statuses/167564219867340800">
<title>Rejets multiples de Hyperacute en l&#x27;absence de l&#x27;activation discernable de compl&#xC3;&#xA9;ment avec Bortezomib.:  http://t.co/OmcZ15Mk</title>
<link>http://twitter.com/inhibiteurs/statuses/167564219867340800</link>
<description><![CDATA[Rejets multiples de Hyperacute en l'absence de l'activation discernable de complément avec Bortezomib.:  http://t.co/OmcZ15Mk]]></description>
</item>

<item rdf:about="http://twitter.com/inhibiteurs/statuses/167564218680356864">
<title>plate-forme Compartiment-sp&#xC3;&#xA9;cifique de formation image de bioluminescence d&#x27;inhibiteur proteasome de bortezomib ... http://t.co/SpqepTdP</title>
<link>http://twitter.com/inhibiteurs/statuses/167564218680356864</link>
<description><![CDATA[plate-forme Compartiment-spécifique de formation image de bioluminescence d'inhibiteur proteasome de bortezomib ... http://t.co/SpqepTdP]]></description>
</item>

<item rdf:about="http://twitter.com/inhibiteurs/statuses/167564217518534656">
<title>Ritonavir agit l&#x27;un sur l&#x27;autre avec Bortezomib pour augmenter la prot&#xC3;&#xA9;ine Ubiquitination en cellules canc&#xC3;&#xA9;reuse... http://t.co/yNauoZQZ</title>
<link>http://twitter.com/inhibiteurs/statuses/167564217518534656</link>
<description><![CDATA[Ritonavir agit l'un sur l'autre avec Bortezomib pour augmenter la protéine Ubiquitination en cellules cancéreuse... http://t.co/yNauoZQZ]]></description>
</item>

<item rdf:about="http://twitter.com/sogaizai/statuses/167562549238317056">
<title>Bortezomib&#xE3;&#x81;&#xAE;&#xE6;&#x8E;&#xA2;&#xE7;&#xB4;&#xA2;&#xE5;&#x8F;&#xAF;&#xE8;&#x83;&#xBD;&#xE3;&#x81;&#xAA;&#xE8;&#xA3;&#x9C;&#xE8;&#xB6;&#
